Symbiosis Pharmaceutical Services Ltd., a CMO and biopharmaceutical development services provider, has purchased new premises in Stirling, Scotland, UK. 
 
The additional space will double the company’s total footprint across the four facilities that it will operate from, increasing manufacturing capacity by 50% in the short-term. As part of a wider strategic growth initiative, this move will strengthen the current GMP manufacturing service offering and further accelerate the delivery of sterile injectable drug products to clients. 
 
The new building is located near Symbiosis’ existing manufacturing cleanrooms, testing labs and GMP warehouse facilities and will bring the company’s total footprint to 43,500 sq.-ft. 
 
The new manufacturing facility also includes plans for two new cleanroom-based production lines to support its pharma and biopharma clients. This will provide further operational flexibility to accommodate a range of custom pharmaceutical manufacturing processes for clients. The increased batch output from the additional production lines will increase Symbiosis’s clinical trial and commercial supply capacity. 
 
The new manufacturing capacity will generate an additional 50 new jobs. The facility fit-out project will be implemented over a three-year period with financial support provided by Barclays Bank PLC for the purchase of the building. 
 
Symbiosis CEO Colin MacKay said, “By investing $2.25 million in the purchase of a 20,000 sq.-ft. building and subsequently equipping it to provide additional world-class sterile manufacturing capacity for our existing and future clients globally represents the next major strategic chapter in the successful and consistently fast-growing trajectory of Symbiosis. It also represents the latest strategic initiative for Symbiosis following on from the addition of labs and the launch of in-house Quality Control (QC) microbiological and analytical testing services last year. The expanded manufacturing capacity will support the strategic ambition of the company to further develop its market presence in its key target markets of North America and the EU.”